ORLANDO -- Postmenopausal women using hormone therapy (HT) saw significantly greater weight loss while taking the dual GIP/GLP-1 receptor agonist tirzepatide than their counterparts not using HT, ...
NEW ORLEANS — Many of us who have tried to lose weight have been told we're just not trying hard enough. And for women after menopause, the newest study suggests it may be something completely out of ...
The GLP-1/GIP dual-receptor agonist tirzepatide led to at least 15% loss of total body fat in premenopausal, perimenopausal, and postmenopausal women, but postmenopausal women taking menopausal ...
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, made by ...
Preclinical data suggest a possible synergistic interaction between estrogen and GLP-1 signaling, explains Regina Castaneda, MD. Midlife weight gain is a persistent challenge for many women, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback